Surrozen (NASDAQ:SRZN) Upgraded by Guggenheim to “Buy” Rating

Guggenheim upgraded shares of Surrozen (NASDAQ:SRZN) from a neutral rating to a buy rating in a research report sent to investors on Friday morning, Marketbeat Ratings reports. Guggenheim currently has $45.00 price objective on the stock.

Surrozen Stock Up 19.4 %

NASDAQ SRZN opened at $17.02 on Friday. The company has a 50-day moving average price of $10.92 and a 200-day moving average price of $9.90. Surrozen has a 52 week low of $6.00 and a 52 week high of $18.17.

Surrozen (NASDAQ:SRZN) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($2.77) by $2.33. The business had revenue of $10.00 million during the quarter. On average, equities analysts predict that Surrozen will post -7.16 EPS for the current fiscal year.

Institutional Trading of Surrozen

Hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC bought a new position in shares of Surrozen in the second quarter worth about $2,050,000. Stonepine Capital Management LLC bought a new stake in Surrozen during the 2nd quarter worth approximately $724,000. CVI Holdings LLC purchased a new position in Surrozen during the second quarter valued at approximately $711,000. Finally, Armistice Capital LLC bought a new position in shares of Surrozen in the second quarter worth approximately $2,080,000. Institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.